非布索坦（非布司他）是什么？

What is (Febuxostat)? Febuxostat (Febuxostat) is a Class A recommendation for the drug treatment of patients with hyperuricemia and gout, which is the first-line drug choice. However, it is not recommended for use in asymptomatic hyperuricemia.

Febuxostat (Febuxostat) is a new generation of xanthine oxidase inhibitor developed by Teijin Corporation of Japan. It is clinically used to treat hyperuricemia (gout). Its structure is completely different from the xanthine oxidase inhibitor drug developed 40 years ago. It is a new and highly effective non-purine xanthine oxidase selective inhibitor. Xanthine oxidase is the key enzyme that promotes uric acid production. Antigout Drugs Gout is a heterogeneous group of diseases that are inherited or acquired disorders of reduced uric acid excretion and purine metabolism. Due to the excessive production of uric acid in the body and the reduced clearance ability of the kidneys, uric acid accumulates in the body, leading to the deposition of urate crystals in joints and various organs. Therefore, the usual treatment for gout is to promote uric acid excretion and inhibit uric acid production, and take appropriate measures to improve related symptoms. The production of uric acid in the body is related to purine metabolism. In the final step of purine metabolism, hypoxanthine generates xanthine under the action of xanthine oxidoreductase (XOR), and then further generates uric acid. Inhibiting the activity of this enzyme can effectively reduce the production of uric acid.

Febuxostat (Febuxostat) can reduce the level of uric acid in the blood of patients with hyperuricemic gout. Clinical studies have shown that Febuxostat (Febuxostat) is safe and effective. Febuxostat (Febuxostat) is metabolized by the liver and does not rely on renal excretion. Therefore, there is no need to reduce the dose for patients with moderate to severe hepatic and renal insufficiency.

In February 2009, the U.S. Food and Drug Administration approved Febuxostat (Febuxostat) for the long-term Chemicalbook treatment of patients with gout and hyperuricemia. (Febuxostat) is the latest generation of non-purine selective xanthine oxidase inhibitor developed in the world. It acts highly selectively on this oxidase to reduce the synthesis of uric acid in the body and reduce the concentration of uric acid, thereby effectively treating ventilation diseases.

Related hot article recommendations: